| SRRA Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the SRRA shares outstanding history going back to 7/16/2015:
Also see: SRRA Market Cap History SRRA YTD Return |
SRRA Shares Outstanding History — Sierra Oncology Share Count Over Time
As of 5/2/2022 Sierra Oncology has 24.42 million SRRA shares outstanding. Investors often track the SRRA shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows SRRA share count trends over time, with 32 historical shares outstanding datapoints presented, dating back to 7/16/2015.
| SRRA Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SRRA Historical Shares Outstanding: +69.22% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SRRA Stock Price Chart |
| About Sierra Oncology Inc |
| Sierra Oncology is a late-stage biopharmaceutical company focused on therapies that treat cancer. Co.'s focus is the development and commercialization of momelotinib, an investigational agent for the treatment of myelofibrosis. Momelotinib is a small-molecule inhibitor of JAK1 (Janus kinase 1), JAK2 (Janus kinase 2) and ACVR1 (Activin A receptor type 1), under development for treatment of patients with myelofibrosis. Co. has conducted a review of data from the two Phase 3 trials of momelotinib, versus ruxolitinib and best available therapy, as well as GS-US-352-1672, a Phase 2, open-label, translational biology trial of momelotinib in transfusion-dependent subjects with myelofibrosis. We show 32 historical shares outstanding datapoints in our coverage of SRRA's shares outstanding history. Understanding the changing numbers of SRRA shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like SRRA versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching SRRA by allowing them to research SRRA shares outstanding history as well as any other stock in our coverage universe. |
| SRRA Current Stock Quote |
Quotes delayed 20 minutes  Free SRRA Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| SRRA Share Performance |
| Shares Outstanding Peers |
| Sierra Oncology (SRRA) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
SRRK Shares Outstanding History SRTS Shares Outstanding History SRZN Shares Outstanding History SSII Shares Outstanding History SSKN Shares Outstanding History STAA Shares Outstanding History STAB Shares Outstanding History STE Shares Outstanding History STEX Shares Outstanding History STIM Shares Outstanding History More Healthcare companies » |
SRRA Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
